Buchumschlag

Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Sriram Balasubramani, Katharina Remih, Anna Sophie Karl, Julia Alexandra Borchert, Christina Schrader, Malin Fromme, Can Kayatekin, Bailin Zhang, Mikhail Levit, Pavithra Krishnaswami, Louise E. van Eekeren, Leo A. B. Joosten, Twan Otten, Petra Tomanová, Pavel Strnad
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Silent But Detectable—High‐Throughput Proteomics to Identify Clinically Significant Liver Disease
von: Emily Stephenson, et al.
Veröffentlicht: (2026)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
von: Leon A. Adams, et al.
Veröffentlicht: (2026)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
von: Jee‐Fu Huang, et al.
Veröffentlicht: (2026)

Regarding: Alpha‐1 antitrypsin deficiency associated with increased risks of skin cancer, leukemia, and hepatic cancer: A nationwide cohort study
von: Malin Fromme, et al.
Veröffentlicht: (2024)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
von: Pojsakorn Danpanichkul, et al.
Veröffentlicht: (2025)

M et ALD : Diagnosis and Prognosis With Non‐Invasive Tests
von: Nikolaj Torp, et al.
Veröffentlicht: (2025)

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation
von: David Mehdi Asgher Niazi, et al.
Veröffentlicht: (2026)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
von: Kelly Torosian, et al.
Veröffentlicht: (2025)

The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions
von: Carlos José Pirola, et al.
Veröffentlicht: (2025)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
von: Glenn Jun Kit Ho, et al.
Veröffentlicht: (2025)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
von: Raj Vuppalanchi, et al.
Veröffentlicht: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
von: Yi‐Ping Hung, et al.
Veröffentlicht: (2024)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
von: Takao Miwa, et al.
Veröffentlicht: (2026)

Burden of Invasive Fungal Diseases in Patients With Alcohol‐Related Hepatitis and Organ Failure
von: Charlotte Mouliade, et al.
Veröffentlicht: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
von: Xinglin Li, et al.
Veröffentlicht: (2026)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects
von: Einar S. Björnsson
Veröffentlicht: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
von: Karen Cheuk‐Ying Ho, et al.
Veröffentlicht: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky
von: Einar S. Björnsson
Veröffentlicht: (2025)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
von: Kaleb Tesfai, et al.
Veröffentlicht: (2026)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
von: Chunlong Liu, et al.
Veröffentlicht: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
von: Ryan Yanzhe Lim, et al.
Veröffentlicht: (2026)

Early‐Life Infections, Antibiotics and Later Risk of Childhood and Early Adult‐Onset Inflammatory Bowel Disease: Pooled Analysis of Two Scandinavian Birth Cohorts
von: Karl Mårild, et al.
Veröffentlicht: (2024)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
von: Muhammad Osama, et al.
Veröffentlicht: (2024)

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease
von: Wah Loong Chan, et al.
Veröffentlicht: (2024)

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
von: Mathias Jachs, et al.
Veröffentlicht: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
von: Raj Vuppalanchi, et al.
Veröffentlicht: (2025)

Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
von: Juan Macias, et al.
Veröffentlicht: (2024)

Editorial: Time to Genotype—Genetic Risk and Prognosis in Steatotic Liver Disease
von: Rosellina M. Mancina, et al.
Veröffentlicht: (2025)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
von: Yuki Utakata, et al.
Veröffentlicht: (2026)

Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?
von: Kelly Torosian, et al.
Veröffentlicht: (2024)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
von: Federica Tavaglione, et al.
Veröffentlicht: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
von: David Mehdi Asgher Niazi, et al.
Veröffentlicht: (2026)

Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Gian Paolo Caviglia, et al.
Veröffentlicht: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
von: Rong‐Xiang Ng, et al.
Veröffentlicht: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2025)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
von: Romeo Kuo‐Cheng Wu, et al.
Veröffentlicht: (2025)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
von: Yu Shi, et al.
Veröffentlicht: (2025)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
von: Zhanbo Qu
Veröffentlicht: (2026)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease
von: Qiong Yi, et al.
Veröffentlicht: (2024)